Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2025)
Historic Non-Current Deffered Revenue for Fennec Pharmaceuticals (FENC) over the last 3 years, with Q3 2025 value amounting to $24.6 million.
- Fennec Pharmaceuticals' Non-Current Deffered Revenue changed 0.0% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $24.6 million for FY2024, which is 122795000.0% up from last year.
- Fennec Pharmaceuticals' Non-Current Deffered Revenue amounted to $24.6 million in Q3 2025, which was down 0.0% from $24.6 million recorded in Q2 2025.
- Over the past 5 years, Fennec Pharmaceuticals' Non-Current Deffered Revenue peaked at $25.0 million during Q1 2024, and registered a low of $2000.0 during Q4 2023.
- In the last 3 years, Fennec Pharmaceuticals' Non-Current Deffered Revenue had a median value of $24.6 million in 2024 and averaged $21.6 million.
- Per our database at Business Quant, Fennec Pharmaceuticals' Non-Current Deffered Revenue surged by 122795000.0% in 2024 and then tumbled by 173.24% in 2025.
- Over the past 3 years, Fennec Pharmaceuticals' Non-Current Deffered Revenue (Quarter) stood at $2000.0 in 2023, then skyrocketed by 1227950.0% to $24.6 million in 2024, then changed by 0.0% to $24.6 million in 2025.
- Its Non-Current Deffered Revenue was $24.6 million in Q3 2025, compared to $24.6 million in Q2 2025 and $24.6 million in Q1 2025.